Wedbush raised the firm’s price target on SpringWorks Therapeutics (SWTX) to $81 from $77 and keeps an Outperform rating on the shares ...

Research by Nationwide found earnings growth had slightly outpaced house price increases in the last year, and combined with a slight reduction in average borrowing costs, it had become more ...